Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in gastric and GEJ adenocarcinoma (KEYNOTE-585 China Extension)
NCT04882241Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04882241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882241.